Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMOTQ1I)

Drug Name
Ondansetron Drug Info
Synonyms
DESMETHYLONDANSETRON; Zofran; Zophren; Zudan; Sandoz ondansetron; ZOFRAN IN PLASTIC CONTAINER; Zofran ODT; GR 38032; GR 38032X; GR38032F; Apo-ondansetron; GR-38032F; Novo-ondansetron; Ondansetron (Zofran); PHL-ondansetron; PMS-ondansetron; Ratio-ondansetron; SN-307; Zofran (TN); Zofran ODT (TN); Ondansetron [USAN:INN:BAN]; Ondansetron (JAN/USP/INN); Ondansetron, (+,-)-Isomer; (RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one; 1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one; 9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one; 9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one; 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
Therapeutic ClassAntiemetics
Cross-matching ID
PubChem CID
4595
ChEBI ID
CHEMBL46
CAS Number
CAS 99614-02-5
TTD Drug ID
D0K7WK
VARIDT Drug ID
DR00909
INTEDE Drug ID
DR1200
ACDINA Drug ID
D00490

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.38 0.00e+0 34/36 (94.44%) MCM5;RPA3;MCM6;...
Spliceosome 2.07 0.00e+0 101/150 (67.33%) PUF60;LSM5;PPIH;...
Mismatch repair 2.03 0.00e+0 22/23 (95.65%) RPA3;PCNA;EXO1;...
Homologous recombination 2.03 0.00e+0 35/41 (85.37%) RPA3;RBBP8;BRCA1;...
Cell cycle 2.00 0.00e+0 110/124 (88.71%) MCM5;CDKN1B;MCM6;...
RNA degradation 1.88 2.62e-3 53/79 (67.09%) PFKL;LSM5;ENO1;...
Purine metabolism 1.74 3.48e-2 102/129 (79.07%) PAPSS1;IMPDH2;GMPS;...
Ovarian steroidogenesis -1.65 2.07e-2 41/51 (80.39%) CYP17A1;SCARB1;ADCY9;...
TNF signaling pathway -1.65 2.10e-2 103/112 (91.96%) CREB3;BIRC3;CASP3;...
Ferroptosis -1.66 2.00e-2 36/41 (87.8%) FTL;TF;STEAP3;...
Systemic lupus erythematosus -1.67 1.72e-2 45/135 (33.33%) HLA-DPA1;HLA-DRA;HLA-DOB;...
NF-kappa B signaling pathway -1.69 1.47e-2 90/104 (86.54%) GADD45B;BCL2A1;BIRC3;...
Glycosphingolipid biosynthesis -1.70 1.14e-2 37/57 (64.91%) ST3GAL5;B3GNT3;ST3GAL4;...
Glycerophospholipid metabolism -1.72 9.93e-3 71/98 (72.45%) PLA2G15;PISD;LCAT;...
Toll-like receptor signaling pathway -1.74 1.04e-2 94/104 (90.38%) MAPK9;MAPK11;MAPK13;...
Graft-versus-host disease -1.74 1.08e-2 32/42 (76.19%) HLA-DPB1;HLA-E;GZMB;...
Asthma -1.77 7.94e-3 25/31 (80.65%) HLA-DPA1;CCL11;HLA-DRA;...
Linoleic acid metabolism -1.79 7.75e-3 21/29 (72.41%) CYP1A2;PLA2G5;PLA2G2D;...
Ether lipid metabolism -1.80 7.53e-3 32/49 (65.31%) PLA2G2D;PLA2G4A;PAFAH1B1;...
Chemokine signaling pathway -1.80 5.96e-3 163/192 (84.9%) GNG13;NFKBIB;ARRB2;...
Necroptosis -1.80 5.61e-3 113/159 (71.07%) IFNAR1;CHMP5;STAT1;...
Leishmaniasis -1.83 2.23e-3 67/77 (87.01%) TAB1;NFKBIA;NFKB1;...
Intestinal immune network for IgA production -1.84 7.94e-4 38/48 (79.17%) HLA-DPA1;HLA-DRA;HLA-DOB;...
NOD-like receptor signaling pathway -1.84 8.51e-4 145/181 (80.11%) NFKBIB;CARD8;IRF7;...
Protein processing in endoplasmic reticulum -1.88 9.17e-4 127/171 (74.27%) ERP29;DNAJC10;HSPA1A;...
Arachidonic acid metabolism -1.91 9.93e-4 48/61 (78.69%) PLA2G2D;PLA2G4A;PTGS2;...
alpha-Linolenic acid metabolism -1.92 1.08e-3 17/25 (68%) PLA2G5;PLA2G2D;PLA2G4A;...
Pertussis -1.93 1.19e-3 64/76 (84.21%) PYCARD;RHOA;ITGB1;...
Phagosome -1.94 1.32e-3 118/152 (77.63%) ATP6V0E2;CTSL;HLA-F;...
Viral protein interaction with cytokine and cytokine re... -1.96 1.49e-3 84/100 (84%) CCR5;CCR1;PPBP;...
Cytokine-cytokine receptor interaction -1.97 0.00e+0 246/295 (83.39%) CCR5;CCR1;AMHR2;...
Malaria -2.00 0.00e+0 44/50 (88%) IL18;SDC1;GYPC;...
Staphylococcus aureus infection -2.06 0.00e+0 72/95 (75.79%) FCGR2B;KRT31;MBL2;...
Complement and coagulation cascades -2.10 0.00e+0 76/85 (89.41%) CD59;VWF;CFHR4;...
Legionellosis -2.11 0.00e+0 51/57 (89.47%) NFKBIA;CASP1;NFKB1;...
IL-17 signaling pathway -2.18 0.00e+0 84/94 (89.36%) NFKBIA;CCL7;NFKB1;...
Rheumatoid arthritis -2.25 0.00e+0 78/93 (83.87%) CSF1;TGFB2;ICAM1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 12.5uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.04uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 12uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H